| Literature DB >> 32822707 |
Andrew M Novick1, Anthony T Scott2, C Neill Epperson2, Christopher D Schneck2.
Abstract
Epidemiological, clinical, and basic research over the past thirty years have described the benefits of estrogen on cognition, mood, and brain health. Less is known about tamoxifen, a selective estrogen receptor modifier (SERM) commonly used in breast cancer which is able to cross the blood-brain barrier. In this article, we review the basic pharmacology of tamoxifenas well as its effects on cognition and mood. The literature reveals an overall impairing effect of tamoxifen on cognition in breast cancer patients, hinting at central antiestrogen activity. On the other hand, tamoxifen demonstrates promising effects in psychiatric disorders, like bipolar disorder, where its therapeutic action may be independent of interaction with estrogen receptors. Understanding the neuropsychiatric properties of SERMs like tamoxifen can guide future research to ameliorate unwanted side-effects and provide novel options for difficult to treat disorders.Entities:
Keywords: Breast cancer; Estrogen; SERM; Tamoxifen
Year: 2020 PMID: 32822707 PMCID: PMC7669724 DOI: 10.1016/j.yfrne.2020.100869
Source DB: PubMed Journal: Front Neuroendocrinol ISSN: 0091-3022 Impact factor: 8.606